secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001437749-25-025827
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q2 net loss $2M, cash ~$1.1M after ATM; runway into Oct 2025
----------------------------------------------------------------------

- Net loss of $2.0M for Q2 2025 vs $1.6M in Q2 2024; R&D expenses up to $1.4M.
- Cash balance $980k at June 30; raised $769k via ATM at avg $2.59/share; runway into Oct 2025.
- R&D expenses increased due to closeout of CardiAMP HF trial and start of CardiAMP HF II enrollment.
- Phase 3 CardiAMP HF data submitted to Japan PMDA; FDA meetings on approvability expected Q4 2025.
- Helix transendocardial delivery system DeNovo 510(k) submission planned Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/0001437749-25-025827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/bcda20250811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer